SCHEMBL4342913

SCHEMBL4342913

NC1(CCC(=O)O)C=CC=C(c2ccccc2)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
FFAR1 O14842 2/20 0.35
CYP1A2 P05177 2/20 0.34
LMNA P02545 2/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HIF1A Q16665 1/20 0.34
NPC1 O15118 1/20 0.34
KEAP1 Q14145 1/20 0.32
HSD17B10 Q99714 3/20 0.31
ALDH1A1 P00352 3/20 0.31
HTT P42858 2/20 0.31
CYP2C9 P11712 1/20 0.31
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
PKM P14618 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
NR4A2 P43354 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6863747 0.81 MAOA (0.37) RAB9ANPC1
SCHEMBL5671293 0.76 NPC1 (0.37) LMNARAB9ANPC1ALDH1A1
SCHEMBL10872336 0.76 SRR (0.33) MEN1KMT2ALMNARAB9ANPC1
Methane SCHEMBL28000918 0.74 NPC1 (0.36) LMNARAB9ANPC1ALDH1A1
SCHEMBL29007685 0.74 HDAC4 (0.32) LMNARAB9ANPC1ALDH1A1TDP1
SCHEMBL4619747 0.73 HDAC4 (0.33) MEN1KMT2ALMNARAB9ASMN1; SMN2
SCHEMBL29170920 0.73 NPC1 (0.42) CYP1A2LMNARAB9ANPC1HSD17B10
SCHEMBL5067245 0.72 HDAC1 (0.35) LMNARAB9ANPC1ALDH1A1
SCHEMBL28926102 0.71 HDAC4 (0.32) LMNARAB9ANPC1ALDH1A1TDP1
SCHEMBL28981671 0.71 HDAC4 (0.32) MEN1KMT2ALMNARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12622857-B2 Skin lightening composition Bella Aurora Labs, S.A. (ES) 2026-05-12 US claimed
CN-114641272-B Skin lightening compositions 贝雅欧若拉实验室公司 2024-06-04 CN claimed
US-20230124126-A1 SKIN LIGHTENING COMPOSITION Bella Aurora Labs, S.A. (ES) 2023-04-20 US claimed
CN-114641272-A Skin lightening compositions 贝雅欧若拉实验室公司 2022-06-17 CN claimed
EP-3791932-B1 SKIN LIGHTENING COMPOSITION BELLA AURORA LABS S A (ES) 2022-03-09 EP claimed
WO-2021052647-A1 SKIN LIGHTENING COMPOSITION Bella Aurora Labs, S.A. (ES) 2021-03-25 WO claimed
EP-3791932-A1 SKIN LIGHTENING COMPOSITION Bella Aurora Labs, S.A. (ES) 2021-03-17 EP claimed
EP-3071177-B1 TARGETED CAPSULES FOR THE DELIVERY OF SKIN WHITENING AGENTS IN THE SKIN INFINITEC ACTIVOS S L (ES) 2017-05-10 EP claimed
EP-3071177-A2 TARGETED CAPSULES FOR THE DELIVERY OF SKIN WHITENING AGENTS IN THE SKIN Infinitec Activos S.L. (ES) 2016-09-28 EP claimed
US-20160250128-A1 TARGETED CAPSULES FOR THE DELIVERY OF SKIN WHITENING AGENTS IN THE SKIN INFINITEC ACTIVOS S.L. (ES) 2016-09-01 US claimed
WO-2015075116-A2 TARGETED CAPSULES FOR THE DELIVERY OF SKIN WHITENING AGENTS IN THE SKIN INFINITEC ACTIVOS, S.L. (ES) 2015-05-28 WO claimed
EP-2875806-A1 Targeted capsules for the delivery of whitening agents in the skin Infinitec Activos, S.L. (ES) 2015-05-27 EP claimed
US-12622857-B2 Skin lightening composition Bella Aurora Labs, S.A. (ES) 2026-05-12 US disclosed
EP-4178595-B1 COMPOSITION COMPRISING A MELANOMA INHIBITORY ACTIVITY PROTEIN (MIA) INHIBITOR PEPTIDE AND SNAIL SECRETION, AND ITS USE IN THE TREATMENT OF VITILIGO BELLA AURORA LABS S A (ES) 2026-04-29 EP disclosed
CN-114641272-B Skin lightening compositions 贝雅欧若拉实验室公司 2024-06-04 CN disclosed
CN-116615218-A Pharmaceutical composition for treating vitiligo 贝雅欧若拉实验室公司 2023-08-18 CN disclosed
EP-1588173-B1 AFFINITY FISHING FOR LIGANDS AND PROTEINS RECEPTORS NOVO NORDISK AS (DK) 2008-11-26 EP disclosed
US-20060257875-A1 Affinity screening using \"one-bead-one-compound\" libraries CARLSBERG A/S (DK) 2006-11-16 US disclosed
EP-1588173-A2 AFFINITY FISHING FOR LIGANDS AND PROTEINS RECEPTORS Carlsberg A/S (DK) 2005-10-26 EP disclosed
WO-2004062553-A2 AFFINITY SCREENING USING “ONE-BEAD-ONE-COMPOUND” LIBRARIES CARLSBERG A/S (DK) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622857-B2 Skin lightening composition MC1R, MC3R, MC5R APEX1 3093/4885MEN1 4288/4885KMT2A 1969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.